Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report)'s share price rose 9.8% during trading on Wednesday . The company traded as high as $13.90 and last traded at $13.86. Approximately 39,270 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 192,962 shares. The stock had previously closed at $12.62.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the company. Citizens Jmp assumed coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They set a "mkt outperform" rating for the company. JMP Securities reissued a "market outperform" rating and set a $28.00 price target on shares of Rapport Therapeutics in a research note on Tuesday.
Get Our Latest Stock Report on Rapport Therapeutics
Rapport Therapeutics Stock Performance
The firm has a fifty day simple moving average of $11.19 and a 200 day simple moving average of $12.15. The company has a market capitalization of $532.90 million and a PE ratio of -4.23.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.09. Research analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.
Institutional Trading of Rapport Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RAPP. TRV GP V LLC acquired a new position in shares of Rapport Therapeutics in the 4th quarter valued at about $126,579,000. Price T Rowe Associates Inc. MD increased its stake in Rapport Therapeutics by 9.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company's stock worth $20,285,000 after buying an additional 95,976 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Rapport Therapeutics by 0.9% in the fourth quarter. Alliancebernstein L.P. now owns 1,098,415 shares of the company's stock valued at $19,486,000 after purchasing an additional 9,494 shares in the last quarter. TRV GP VI LLC purchased a new stake in shares of Rapport Therapeutics in the fourth quarter valued at approximately $17,194,000. Finally, Geode Capital Management LLC grew its position in shares of Rapport Therapeutics by 4.4% in the fourth quarter. Geode Capital Management LLC now owns 210,676 shares of the company's stock valued at $3,738,000 after purchasing an additional 8,928 shares in the last quarter.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
